184 related articles for article (PubMed ID: 31090264)
21. MED1 may explain the interaction between receptor tyrosine kinases and ERα66 in the complicated network of Tamoxifen resistance.
Mansouri S; Naghavi-Al-Hosseini F; Farahmand L; Majidzadeh-A K
Eur J Pharmacol; 2017 Jun; 804():78-81. PubMed ID: 28322840
[TBL] [Abstract][Full Text] [Related]
22. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
Zhang J; Wang Q; Wang Q; Cao J; Sun J; Zhu Z
Cell Mol Life Sci; 2020 Feb; 77(4):559-572. PubMed ID: 31471681
[TBL] [Abstract][Full Text] [Related]
24. Loss of Med1/TRAP220 promotes the invasion and metastasis of human non-small-cell lung cancer cells by modulating the expression of metastasis-related genes.
Kim HJ; Roh MS; Son CH; Kim AJ; Jee HJ; Song N; Kim M; Seo SY; Yoo YH; Yun J
Cancer Lett; 2012 Aug; 321(2):195-202. PubMed ID: 22342682
[TBL] [Abstract][Full Text] [Related]
25. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
26. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
27. Disruption of cardiac Med1 inhibits RNA polymerase II promoter occupancy and promotes chromatin remodeling.
Hall DD; Spitler KM; Grueter CE
Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H314-H325. PubMed ID: 30461303
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
29. Mediator subunit MED1 is a T3-dependent and T3-independent coactivator on the thyrotropin β gene promoter.
Matsui K; Oda K; Mizuta S; Ishino R; Urahama N; Hasegawa N; Roeder RG; Ito M
Biochem Biophys Res Commun; 2013 Oct; 440(1):184-9. PubMed ID: 24055033
[TBL] [Abstract][Full Text] [Related]
30.
Immarigeon C; Bernat-Fabre S; Augé B; Faucher C; Gobert V; Haenlin M; Waltzer L; Payet A; Cribbs DL; Bourbon HG; Boube M
Mol Cell Biol; 2019 Apr; 39(7):. PubMed ID: 30670567
[TBL] [Abstract][Full Text] [Related]
31. The transcriptional coactivator DRIP/mediator complex is involved in vitamin D receptor function and regulates keratinocyte proliferation and differentiation.
Oda Y; Chalkley RJ; Burlingame AL; Bikle DD
J Invest Dermatol; 2010 Oct; 130(10):2377-88. PubMed ID: 20520624
[TBL] [Abstract][Full Text] [Related]
32. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer.
Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC
J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681
[TBL] [Abstract][Full Text] [Related]
33. Combined Blockade of Activating
Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
[TBL] [Abstract][Full Text] [Related]
34. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Chen Z; Wang Y; Warden C; Chen S
J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
[TBL] [Abstract][Full Text] [Related]
35. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
[TBL] [Abstract][Full Text] [Related]
36. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.
Patki M; Salazar Md; Trumbly R; Ratnam M
Biochem Biophys Res Commun; 2015 Feb; 457(3):404-11. PubMed ID: 25582774
[TBL] [Abstract][Full Text] [Related]
39. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
40. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
